10 Participants Needed

[11C]-NOP46 PET/CT Scan for Chronic Pain

RA
MD
AM
Overseen ByAkiva Mintz, MD, PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial involves giving a small amount of a new drug called [11C]-NOP46 to people with long-term pain. The drug travels to the painful areas in the body, and a camera takes pictures of these areas. This could help doctors better understand and treat long-term pain.

Do I have to stop taking my current medications for the trial?

Yes, you must stop taking pain medications 48 hours before the agent administration. If you can't, you may be withdrawn or rescheduled. Other medications may also be restricted if deemed inappropriate by the investigator.

Will I have to stop taking my current medications?

Yes, you will need to stop taking pain medications for 48 hours before the study agent is given. If you take pain medication within this time, you may be withdrawn from the study or rescheduled.

What safety data exists for [11C]-NOP46 PET/CT scans for chronic pain?

The safety data for [11C]-NOP46, also known as (11)C-NOP-1A, primarily comes from studies on its use as a PET radioligand for imaging nociceptin/orphanin FQ peptide (NOP) receptors. Research has been conducted in both rhesus monkeys and humans to assess its ability to quantify NOP receptors and estimate its radiation safety profile. These studies indicate that (11)C-NOP-1A has a high affinity for NOP receptors and an appropriate safety profile for use in brain imaging. However, specific safety data for its use in chronic pain treatment is not directly addressed in the provided research.12345

Is the [11C]-NOP46 PET/CT scan safe for humans?

Research on a similar compound, (11)C-NOP-1A, used for imaging in humans, suggests it has a safe radiation profile based on studies in both monkeys and humans.12345

Is the drug [11C]-NOP46 a promising treatment for chronic pain?

Yes, the drug [11C]-NOP46 shows promise as a treatment for chronic pain. It targets a new type of opioid receptor, which is important in managing pain. The drug has been successfully used in brain imaging to study these receptors, which could help in understanding and treating pain more effectively.24678

How does the [11C]-NOP46 PET/CT Scan treatment for chronic pain differ from other treatments?

The [11C]-NOP46 PET/CT Scan is unique because it uses a PET imaging technique to visualize the nociceptin/orphanin FQ peptide (NOP) receptors in the brain, which are a new class of opioid receptors potentially involved in pain. This approach is different from traditional pain treatments as it focuses on identifying specific brain receptor activity, which could lead to more targeted and personalized pain management strategies.24678

What data supports the idea that [11C]-NOP46 PET/CT Scan for Chronic Pain is an effective treatment?

The available research does not provide any data supporting the effectiveness of [11C]-NOP46 PET/CT Scan for Chronic Pain. The studies mentioned focus on different imaging agents and conditions, such as cancer detection and personalized radiopharmaceuticals, but do not address chronic pain or the specific treatment in question.910111213

Who Is on the Research Team?

AM

Akiva Mintz, MD, PhD

Principal Investigator

Columbia University

Are You a Good Fit for This Trial?

This trial is for adults who can consent to participate. Healthy volunteers must not have chronic pain or be pregnant, and agree to use contraception. Patients with focal pain should experience moderate to severe pain (>4 on the Visual Analogue Scale) and also agree to contraceptive measures.

Inclusion Criteria

I agree to use birth control or abstain from sex during the study.
I am currently experiencing pain from a specific injury and am seeing a doctor for it.
I am a volunteer without any ongoing pain from an injury.
See 4 more

Exclusion Criteria

Concomitant medication use (including suspected illicit drugs use) that, in the judgment of the investigator, would make the participant inappropriate for enrollment.
I do not have widespread pain currently.
I am not pregnant or breastfeeding.
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Stage 1: Healthy Volunteers

Five healthy volunteers receive a microdose of [11C]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes to evaluate biodistribution and derive dosimetry estimates.

1 day
1 visit (in-person)

Stage 2: Individuals with Focal Pain

Up to 30 subjects with focal pain receive a microdose of [11C]-NOP46 and undergo PET/CT scans for up to 60 minutes to determine scanning parameters.

1 day
1 visit (in-person)

Follow-up

Participants are monitored for physiologic effects and uptake ratio for 48 hours post-scan.

48 hours

What Are the Treatments Tested in This Trial?

Interventions

  • [11C]-NOP46
Trial Overview The study tests a new radiotracer called [11C]-NOP46 using PET/CT scans in two stages: first in five healthy individuals for safety, then in thirty patients with chronic pain if no toxicities are found.
How Is the Trial Designed?
2Treatment groups
Experimental Treatment
Group I: Individuals with Focal PainExperimental Treatment2 Interventions
In Stage 2, up to 30 subjects with focal pain will receive a microdose of \[11C\]-NOP46 and undergo PET/CT scans for up to 60 minutes in length. The results of Stage 1 will inform the scanning parameters (uptake period, scan length, reconstruction parameters, etc.) for Stage 2.
Group II: Healthy VolunteersExperimental Treatment2 Interventions
In Stage 1, five healthy volunteers will receive a microdose of \[11C\]-NOP46 and undergo serial whole body PET/CT scans for up to 240 minutes post-administration. These image sets will be used to evaluate \[11C\]-NOP46 biodistribution and derive dosimetry estimates.

Find a Clinic Near You

Who Is Running the Clinical Trial?

Columbia University

Lead Sponsor

Trials
1,529
Recruited
2,832,000+

Akiva Mintz

Lead Sponsor

Trials
1
Recruited
40+

Published Research Related to This Trial

The study developed a targeted imaging agent, CD166tp-G18C, which effectively binds to colorectal cancer stem cells (CRCSCs) in a mouse model, indicating its potential for detecting these cells in cancer therapy.
Using indium-111 to label the CD166tp-G18C probe, researchers found significantly enhanced imaging in tumor tissues, suggesting that this method could improve the detection and monitoring of colorectal cancer stem cells in patients.
Indium-111-labeled CD166-targeted peptide as a potential nuclear imaging agent for detecting colorectal cancer stem-like cells in a xenograft mouse model.Guan, SS., Wu, CT., Liao, TZ., et al.[2020]
The novel [64Cu]Cu-NOTA-aCD40 immunoPET tracer showed significantly higher accumulation in pancreatic tumors compared to a control tracer, indicating its specificity for targeting CD40+ tumors in a mouse model.
Safety assessments for human imaging with [64Cu]Cu indicated a favorable organ dose profile, particularly with a lower injected mass, suggesting it could be a safe option for imaging in clinical settings.
Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice.Aghevlian, S., Wu, B., Raie, MN., et al.[2022]
A 64Cu-labeled antibody targeting CD146 was developed and successfully used for PET imaging in six lung cancer models, showing a strong correlation between CD146 expression and tumor uptake of the radiotracer.
The highest tumor uptake of the radiotracer was observed in lung cancer models with high CD146 expression, indicating its potential for monitoring tumor progression and tailoring treatment strategies based on CD146 levels.
ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer.Sun, H., England, CG., Hernandez, R., et al.[2018]

Citations

Indium-111-labeled CD166-targeted peptide as a potential nuclear imaging agent for detecting colorectal cancer stem-like cells in a xenograft mouse model. [2020]
Pre-clinical evaluation of immunoPET imaging using agonist CD40 monoclonal antibody in pancreatic tumor-bearing mice. [2022]
ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer. [2018]
Positron Emission Tomography Imaging of Programmed Death 1 Expression in Cancer Patients Using 124I-Labeled Toripalimab: A Pilot Clinical Translation Study. [2023]
An approach to develop personalized radiopharmaceuticals by modifying 2-[18F]fluoro-2-deoxy-D-glucose (2-[18F]FDG). [2023]
Brain and whole-body imaging in rhesus monkeys of 11C-NOP-1A, a promising PET radioligand for nociceptin/orphanin FQ peptide receptors. [2022]
Brain and whole-body imaging of nociceptin/orphanin FQ peptide receptor in humans using the PET ligand 11C-NOP-1A. [2023]
Synthesis and evaluation of radioligands for imaging brain nociceptin/orphanin FQ peptide (NOP) receptors with positron emission tomography. [2023]
9.United Arab Emiratespubmed.ncbi.nlm.nih.gov
PET imaging of opioid receptors in pain: progress and new directions. [2019]
The nociceptin/orphanin FQ receptor system as a target to alleviate cancer-induced bone pain in rats: Model validation and pharmacological evaluation. [2023]
11.United Statespubmed.ncbi.nlm.nih.gov
Retest imaging of [11C]NOP-1A binding to nociceptin/orphanin FQ peptide (NOP) receptors in the brain of healthy humans. [2023]
12.United Statespubmed.ncbi.nlm.nih.gov
Imaging as a Pain Biomarker. [2022]
13.United Statespubmed.ncbi.nlm.nih.gov
Development of LC-MS/MS-based receptor occupancy tracers and positron emission tomography radioligands for the nociceptin/orphanin FQ (NOP) receptor. [2022]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security